Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-08-03
Based on 1225 first isolates · PHC-N · Cystitis (lower UTI) · 2024-08-04 → 2025-08-03
Health centre North
Per-organism detail: PHC-N urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 83 % (80 %–85 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (8 %), Pseudomonas aeruginosa (5 %), Klebsiella pneumoniae (4 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
83 %
90 %
n = 125
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
83 %
80 %
n = 125
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
80 %
86 %
n = 125
ciprofloxacin CIP
trend · Escherichia coli
77 %
85 %
n = 125
mecillinam MEC
trend · Escherichia coli lower UTI only
76 %
80 %
n = 125
ceftriaxone CRO
trend · Escherichia coli
75 %
77 %
n = 125
trimethoprim TMP
trend · Escherichia coli lower UTI only
72 %
68 %
n = 125
71 %
76 %
n = 125
52 %
55 %
n = 125
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
14 %
8 %
n = 125
5 %
10 %
n = 125
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
2 %
n = 125

Most likely organisms for this profile

Escherichia coli
51 %
Klebsiella pneumoniae
12 %
Enterococcus faecalis
10 %
Proteus mirabilis
8 %
Pseudomonas aeruginosa
5 %
Citrobacter freundii
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.